Guardion Health Sciences (GHSI) Climbs On Development News

Guardion Health Sciences GHSI Stock News

Guardion Health Sciences Inc (NASDAQ: GHSI) is having a great start to the trading session this morning, up around 20%. The gains come after the company announced that it is working on a proprietary formulation to provide immuno-support and anti-inflammatory benefits targeting upper respiratory tract issues. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

GHSI Stock Climbs On Upper Respiratory Tract News

In the press release, Guardion Health Sciences said that it is working on a unique proprietary formulation to provide immuno-support and anti-inflammatory benefits that target upper respiratory tract infections. 

The company said that these efforts are being spearheaded by its recently acquired Nutriguard business line. This recently acquired asset formulates high-quality, scientifically-credible, condition-specific nutraceuticals. As with all nutraceuticals, the comapny’s products work to supplemnt diet and assist in the prevention and management of diseases and other conditions. 

In the release, GHSI said that the new product will be called acuMMUNE. The product was designed by the company’s internal product and technology design team. It’s also the first product to be introduced by Guardion after the acquisition of NutriGuard. 

The formulation supports effective function of interferon mediated anti-viral mechanisms while also mitigating the excessive lung inflammation that can lead to harsh symptoms and death caused by severe lung infections associated with viral infections. 

The product launch is expected to come quickly as well. In fact, GHSI said that it is currently in talks surrounding the manufacture of the product and estimate that it will be available for sale in April of this year. 

In a statement, Michael Favish, CEO at GHSI, had the following to offer:

We believe that this unique product can provide a timely and effective immune response protocol to address respiratory tract symptoms associated with global pandemics.

The Timing Couldn’t Be More Perfect

With the coronavirus spreading throughout China and around the world, fear of becoming ill is spreading among consumers. Keep in mind, the coronavirus is an upper respiratory tract condition. 

With the new product targeting upper respiratory tract issues being released by GHSI, there’s a strong chance that the product will be met with incredible demand. All in all, the timing couldn’t be more perfect for an announcement like this. 

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story!

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.